Validation of Promarker^®D
in the CANVAS Trial

Predicting renal function decline in Patients with Type 2 diabetes using the Promarker^®D test

Chronic kidney disease (CKD) is one of the most serious and underdiagnosed complications of type 2 diabetes. Traditional diagnostic methods (e.g. eGFR and uACR) often fail to detect early risk, leaving clinicians with limited time to intervene before irreversible renal damage occurs.

The prognostic ability of Promarker^®D to predict CKD was evaluated in the CANVAS (Canagliflozin Cardiovascular Assessment Study) — one of the largest clinical trials of SGLT2 Inhibitor therapy for type 2 diabetes. A major breakthrough for improved patient management for CKD risk, the study analyzed 3,568 patients to validate the ability of Promarker^®D to predict decline in renal function up to four years in advance of standard clinical markers.